Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 7/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32659768 | 1.00 | VCP (0.48) | VCPCYP1A2MAPK1KDM4ETP53 | |
| SCHEMBL23630571 | 0.92 | PIK3CD (0.50) | VCPCYP1A2MAPK1KDM4ETP53 | |
| SCHEMBL32659771 | 0.92 | PIK3CD (0.50) | VCPCYP1A2MAPK1KDM4ETP53 | |
| SCHEMBL32659777 | 0.87 | PIK3CD (0.39) | VCPPIK3CDPIK3CBPIK3CGSRC | |
| SCHEMBL23630535 | 0.87 | PIK3CD (0.39) | VCPPIK3CDPIK3CBPIK3CGSRC | |
| SCHEMBL23630566 | 0.83 | PIK3CD (0.53) | VCPCYP1A2MAPK1KDM4ETP53 | |
| SCHEMBL32659750 | 0.83 | PIK3CD (0.53) | VCPCYP1A2MAPK1KDM4ETP53 | |
| SCHEMBL23630581 | 0.79 | SRC (0.53) | PIK3CDPIK3CBPIK3CGSRCEGFR | |
| SCHEMBL32659753 | 0.79 | SRC (0.53) | PIK3CDPIK3CBPIK3CGSRCEGFR | |
| SCHEMBL23630573 | 0.77 | SRC (0.57) | TP53MEN1KMT2ASRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| WO-2021142170-A1 | MODIFIED PYRROLO- AND PYRAZOLO- PYRIMIDINES FOR PROSTATE CANCER THERAPY | UNIVERSITY OF WASHINGTON (US) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | PDK2, PDK1, PC | VCP 2215/4885CYP1A2 2655/4885MAPK1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.